Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
NPM1 - ALK ALK I1171T Crizotinib anaplastic large cell lymphoma resistant detail...
NPM1 - ALK Crizotinib anaplastic large cell lymphoma sensitive detail...
NPM1 - ALK ALK amp NPM1 amp Crizotinib anaplastic large cell lymphoma resistant detail...
NPM1 - ALK ALK amp NPM1 amp Ceritinib anaplastic large cell lymphoma resistant detail...
NPM1 - ALK ALK amp NPM1 amp Alectinib anaplastic large cell lymphoma decreased response detail...
NPM1 - ALK Alectinib anaplastic large cell lymphoma sensitive detail...
NPM1 - ALK ASP3026 anaplastic large cell lymphoma sensitive detail...
NPM1 - ALK Ceritinib anaplastic large cell lymphoma sensitive detail...
NPM1 - ALK ALK amp NPM1 amp ASP3026 anaplastic large cell lymphoma resistant detail...
NPM1 - ALK ALK amp NPM1 amp Brigatinib anaplastic large cell lymphoma resistant detail...
NPM1 - ALK Brigatinib anaplastic large cell lymphoma sensitive detail...
NPM1 - ALK ALK F1174V ALK L1198F Brigatinib anaplastic large cell lymphoma resistant detail...
NPM1 - ALK ALK L1122V ALK L1196M Brigatinib anaplastic large cell lymphoma resistant detail...
NPM1 - ALK ALK S1206C Brigatinib anaplastic large cell lymphoma resistant detail...
NPM1 - ALK ALK I1171S Crizotinib anaplastic large cell lymphoma resistant detail...
NPM1 - ALK ALK R1192P Crizotinib anaplastic large cell lymphoma resistant detail...
NPM1 - ALK ALK G1269A Crizotinib anaplastic large cell lymphoma resistant detail...
NPM1 - ALK ALK F1174L Ceritinib anaplastic large cell lymphoma resistant detail...
NPM1 - ALK ALK T1151M Ceritinib anaplastic large cell lymphoma resistant detail...
NPM1 - ALK ALK F1174I ASP3026 anaplastic large cell lymphoma resistant detail...
NPM1 - ALK ALK C1156Y ASP3026 anaplastic large cell lymphoma resistant detail...
NPM1 - ALK ALK I1171T ASP3026 anaplastic large cell lymphoma resistant detail...
NPM1 - ALK ALK I1171N ASP3026 anaplastic large cell lymphoma resistant detail...
NPM1 - ALK ALK G1128S ASP3026 anaplastic large cell lymphoma resistant detail...
NPM1 - ALK ALK C1156F ALK D1203N ASP3026 anaplastic large cell lymphoma resistant detail...
NPM1 - ALK ALK E1210K ASP3026 anaplastic large cell lymphoma resistant detail...
NPM1 - ALK ALK C1156F ASP3026 anaplastic large cell lymphoma resistant detail...
NPM1 - ALK ALK N1178H ASP3026 anaplastic large cell lymphoma resistant detail...
NPM1 - ALK ALK L1196Q ASP3026 anaplastic large cell lymphoma sensitive detail...
NPM1 - ALK ALK L1196Q Crizotinib anaplastic large cell lymphoma resistant detail...
NPM1 - ALK Entrectinib anaplastic large cell lymphoma sensitive detail...
ALK fusion Crizotinib anaplastic large cell lymphoma sensitive detail...
Unknown unknown Brentuximab vedotin anaplastic large cell lymphoma not applicable detail...
NPM1 - ALK CEP-28122 anaplastic large cell lymphoma sensitive detail...
ALK negative Brentuximab vedotin anaplastic large cell lymphoma predicted - sensitive detail...
ALK rearrange N/A anaplastic large cell lymphoma not applicable detail...
ALK rearrange Crizotinib anaplastic large cell lymphoma sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00585195 Phase I Crizotinib + Itraconazole Crizotinib + Rifampin A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer (PROFILE 1001) Active, not recruiting
NCT00671112 Phase I Bortezomib + Everolimus Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma Terminated
NCT00939770 Phase Ib/II Crizotinib Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma Completed
NCT01196208 Expanded access Brentuximab vedotin A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001 No longer available
NCT01449461 Phase Ib/II Brigatinib A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113 Completed
NCT01606878 Phase I Dexamethasone + Doxorubicin + Vincristine Sulfate Cyclophosphamide + Topotecan Crizotinib Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma Completed
NCT01686165 Phase II Belinostat Rituximab Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma Completed
NCT01979536 Phase II Crizotinib Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma Suspended
NCT02203903 Phase I MultiTAA-specific T cells Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies (RESOLVE) Recruiting
NCT02232516 Phase II Lenalidomide + Romidepsin Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma Recruiting
NCT02420795 Phase Ib/II ONC201 Study of Oral ONC201 in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma Recruiting
NCT02464228 Phase II Tipifarnib Study of Tipifarnib in Subjects With Relapsed or Refractory Peripheral T-Cell Lymphoma Active, not recruiting
NCT02568267 Phase II Entrectinib Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2) Recruiting
NCT02572453 Phase II Onalespib Testing AT13387 (Onalespib) in Patients With Relapsed/Refractory ALK+ Anaplastic Large Cell Lymphoma (ALCL), Mantle Cell Lymphoma (MCL), and BCL6+ Diffuse Large B Cell Lymphoma (DLBCL) Active, not recruiting
NCT02616965 Phase I Brentuximab vedotin + Romidepsin A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma Recruiting
NCT02663297 Phase I ATLCAR.CD30 cells Administration of T Lymphocytes for Prevention of Relapse of Lymphomas Recruiting
NCT02722668 Phase II Cyclophosphamide + Fludarabine + Mycophenolate mofetil Sirolimus anti-thymocyte globulin UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep Recruiting
NCT02729961 Phase Ib/II Brentuximab vedotin + Ceritinib Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma Withdrawn
NCT02978625 Phase II Nivolumab + Talimogene laherparepvec Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers Recruiting
NCT03017820 Phase I VSV-hIFNbeta-NIS VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, or T-cell Lymphoma Recruiting
NCT03049449 Phase I ATLCAR.CD30 cells Cyclophosphamide + Fludarabine T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas Recruiting
NCT03075553 Phase II Nivolumab Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Terminated
NCT03081910 Phase I CD5 CAR T cells Cyclophosphamide + Fludarabine Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen (MAGENTA) Recruiting
NCT03372057 Phase II Duvelisib A Study of Duvelisib in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL) Recruiting
NCT03586999 Phase Ib/II Cyclophosphamide + Doxorubicin + Etoposide + Nivolumab + Prednisone + Vincristine Sulfate Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas Recruiting
NCT03602157 Phase I ATLCAR.CD30.CCR4 cells Bendamustine + Fludarabine ATLCAR.CD30 cells + ATLCAR.CD30.CCR4 cells Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL Recruiting
NCT03674411 Phase II Busulfan + Filgrastim + Fludarabine + Melphalan + MGTA-456 + Mycophenolate mofetil + Tacrolimus Cyclophosphamide + Filgrastim + Fludarabine + MGTA-456 + Mycophenolate mofetil + Tacrolimus Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy Active, not recruiting
NCT03719898 Phase II Brigatinib Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma Recruiting
NCT03902184 Phase II Gemcitabine + Lacutamab + Oxaliplatin Lacutamab IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma (TELLOMAK) Recruiting
NCT03905135 Phase I Avelumab + rhIL-15 Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies Recruiting
NCT03947255 Phase II Brentuximab vedotin A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma Recruiting
NCT04074746 Phase I Cyclophosphamide + Fludarabine AFM13 Bispecific Antibody AFM13 Combined With NK Cells for Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas Recruiting
NCT04234048 Phase I Fenretinide Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma Not yet recruiting